Reach Us +441902928240

Welcome to the Journal

ISSN: 2041-6792 | *Journal Impact Factor: 2.75 | NLM ID: 101554582 Journal Membership services

Clinical Investigation (2041-6792) plays significant role in the diagnosis, therapy and cure of diseases apart from new drug development and delivery. The Clinical Investigation Journal offers an Open Access platform to the scholars, amateurs, clinical practitioners and students that are keen in contributing their findings in this field.

Clinical Investigation caters to the clinical drug development and methodology, facilitating rapid publication of research outcome on new drug data from human studies. The journal includes topics like safety and effectiveness of medications, devices, diagnostic products and treatment regimens intended for human use. Also the journal publishes expert analysis of ongoing Phase I–IV trials and perspectives on how to run future trials.

The journal offers thoroughly reviewed original research as research articles, review articles, Clinical Trial Protocols, Clinical Trial Perspectives, Clinical Trial Outcomes, Clinical Trial Reports, Clinical Trial Methodologies, Clinical Trial phase I-IV findings, Commentaries on Clinical trials, case studies, commentaries, Short Communication, and Letters to the Editors in the areas not limited to Regulations and guidelines on drug development and delivery, legal and ethical issues of clinical trials, issues of testing of novel drugs, new medical procedure, new medical devices etc.

Submit your manuscripts online at Editorial Manager®:

Contact Editorial Office or send attachment of manuscript at any of the following mail id: [email protected] / [email protected] / [email protected] / [email protected]

*2017 Journal Impact Factor was established by dividing the number of articles published in 2015 and 2016 with the number of times they are cited in 2017 based on Google Scholar Citation Index database. If 'X' is the total number of articles published in 2015 and 2016, and 'Y' is the number of times these articles were cited in indexed journals during 2017 then, journal impact factor = Y/X

Recently Published Articles

Research Article p. 147-154

A comparison of liprotamase, a non-porcine pancreatic enzyme replacement therapy, to porcine extracted pancrelipase in a noninferiority randomized clinical trial in patients with cystic fibrosis

Author(s): Michael W Konstan, Jeffrey S Wagener, Michael Wilschanski, István Laki, Steven R Boas, Dorota Sands, Monica Gangal, Renee S Martin, William Shanahan, James Pennington

Objective: Porcine derived enzymes are used for pancreatic enzyme replacement therapy in patients with cystic fibrosis (CF). Liprotamase is a biotechnology-derived, non-porcine, enzyme repla..